Polymorphisms in the PDE3A gene
First Claim
Patent Images
1. A method for treating a human patient with heart failure comprising treating the patient with an effective amount of a PDE3A inhibitor after the patient is determined to be homozygous for an insertion of an ectotropic viral integration site-1 (Evi-1) binding site in the phosphodiesterase type 3A (PDE3A) gene promoter, wherein the Evi-1 binding site insertion is 85% identical to SEQ ID NO:
- 2 and is located within 2000 nucleotides 5′
of the PDE3A gene transcriptional initiation site and wherein the PDE3A inhibitor is amrinone, cilostazol, milrinone, quazinone, siguazodan, trequinsin, or enoximone.
1 Assignment
0 Petitions
Accused Products
Abstract
Embodiments of the invention are directed to identifying or treating a patient that would benefit from phosphodiesterase inhibitor therapy.
-
Citations
12 Claims
-
1. A method for treating a human patient with heart failure comprising treating the patient with an effective amount of a PDE3A inhibitor after the patient is determined to be homozygous for an insertion of an ectotropic viral integration site-1 (Evi-1) binding site in the phosphodiesterase type 3A (PDE3A) gene promoter, wherein the Evi-1 binding site insertion is 85% identical to SEQ ID NO:
- 2 and is located within 2000 nucleotides 5′
of the PDE3A gene transcriptional initiation site and wherein the PDE3A inhibitor is amrinone, cilostazol, milrinone, quazinone, siguazodan, trequinsin, or enoximone. - View Dependent Claims (2, 3, 4, 5, 6, 7)
- 2 and is located within 2000 nucleotides 5′
-
8. A method for treating a patient with heart failure comprising treating the patient with an effective amount of a enoximone after the patient is determined to be homozygous for an insertion having a sequence identical to SEQ ID NO:
- 2 and located within 2000 nucleotides 5′
of the PDE3A gene transcriptional initiation site. - View Dependent Claims (9, 10, 11, 12)
- 2 and located within 2000 nucleotides 5′
Specification